<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81951">
  <stage>Registered</stage>
  <submitdate>4/04/2007</submitdate>
  <approvaldate>30/06/2008</approvaldate>
  <actrnumber>ACTRN12608000307303</actrnumber>
  <trial_identification>
    <studytitle>A randomised, controlled comparison of uridine, pravastatin or uridine plus pravastatin to accelerate recovery of lipoatrophy in Human immunodeficiency virus (HIV)-infected adults</studytitle>
    <scientifictitle>A randomised, controlled comparison of uridine, pravastatin or uridine plus pravastatin to accelerate recovery of lipoatrophy in Human immunodeficiency virus (HIV)-infected adults</scientifictitle>
    <utrn />
    <trialacronym>URISTAT study</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV</healthcondition>
    <healthcondition>lipoatrophy</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A randomised, controlled comparison of uridine 36g three times a day for the first 10 days of each month , pravastatin 40 mg daily or uridine 36g three times a day for the first 10 days of each month plus pravastatin 40 mg daily to accelerate recovery of lipoatrophy in HIV-infected adults. Both drugs are taken orally for 24 weeks</interventions>
    <comparator>Human immunodeficiency virus (HIV)-infected adults with lipoatrophy on kaletra (2 x 200mg/50mg tablets, orally 2 times a day for 24 weeks) containing regimen of anti retrovirals</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Difference in changes in limb fat mass Dual-Energy X-ray Absorptiometry (DEXA)</outcome>
      <timepoint>Weeks 4, 16, 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety ( clinical, chemistry, haematology) and tolerability. Specific indicators are complete blood count, biochemistry including Liver function tests, blood urea and electrolytes, lactate, amylase, creatinine kinase. Indicators for tolerability are treatment adherence rate, incidence of adverse events as reported by participants at regular study visits (weeks 2,4,5 8,16,28)</outcome>
      <timepoint>weeks 0, 2,4,5 8,16,28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Intra-abdominal fat area(VAT) and subcutaneous visceral fat area (SAT) measured by 3-slice computerised tomography (CT) scan at the lumbar (L)2-3,L3-4 and L4-5 vertebral levels
Measured by 3-slice CT scan</outcome>
      <timepoint>weeks 4 and 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>fasting lipids (total, non-high density lipid (HDL) and low density lipid (LDL) cholestrol , triglycerides). Measured by blood sample analysis</outcome>
      <timepoint>at screening visit, weeks 0, 4, 8, 16 and 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>fasting glucose, insulin and estimated insulin resistance (HOMA) Measured by blood sample analysis</outcome>
      <timepoint>at screening visit, weeks 4, 8, 16 and 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>lactate Measured by blood sample analysis</outcome>
      <timepoint>at screening visit, weeks 0, 4, 8, 16 and 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HIV viral load
Measured by blood sample analysis</outcome>
      <timepoint>at screening visit, weeks 0, 4, 16 and 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mitochondrial function in peripheral blood monocytes. Measured by blood sample analysis</outcome>
      <timepoint>Weeks 4 and 16</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. subcutaneous lipoatrophy in at least 2 body sites, at least one of which is moderate or severe according to both the patient and the doctor
2. HIV viral load &lt;50 copies /ml plasma for at least 3 months
3. use of stable HARRT not including tNRTI for at least 3 months
4. no grade 3or 4 laboratory values at baseline</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. zidovudine (AZT) or stavudine (d4T) in preceding 12 weeks (12/52)
2. ongoing opportunistic infection , other AIDS -defining illness or other illness that would interfere with participation
3. clinically significant renal or hepatic disease
4.lipid levels necessitating statin treatment
5. anabolic steriods, growth hormone, or supra-physiological corticosteriod doeses.
6. pregnancy or breast feeding
7. allergy to any component of the randomised drugs
8. prior use of uridine</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>allocation involved contacting the holder of the allocation schedule who was off site</concealment>
    <sequence>block randomization</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/08/2006</anticipatedstartdate>
    <actualstartdate>1/02/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate>28/11/2008</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St Vincent's Hospital , Sydney</primarysponsorname>
    <primarysponsoraddress>390 Victoria St
Darlinghurst, NSW 2010
Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Abbott</fundingname>
      <fundingaddress>32-34 Lord Street
Botany NSW 2019
Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>St Vincent's Hospital, Sydney</fundingname>
      <fundingaddress>390 Victoria St
Darlinghurst, NSW 2010
Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Prospective, randomised, 28-week trial in 40 patients.
The first step: forty (40) eligible, consented participants will switch from existing PI or NNRTI and commence ritonavir-boosted lopinavir at week 0 (2 tablets twice-daily).
The second step: patients on lopinavir/r will be randomised to initiate study therapy at week 4 (4 weeks after initiation of lopinavir/r) for 24 weeks. 
Eligible subjects will be randomised equally (10 patients per group) to:
1. uridine (36g tid for 10 days per month) 
2. pravastatin (40 mg nocte) 
3. uridine (36g tid for 10 days per month) + pravastatin (40 mg nocte)  
4. delayed treatment arm (DTA) 
All patients will be offered the combination of pravastatin and uridine for 24 weeks from week 28.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital, Sydney</ethicname>
      <ethicaddress>390 Victoria St Darlinghurst, NSW 2010 Australia</ethicaddress>
      <ethicapprovaldate>15/05/2006</ethicapprovaldate>
      <hrec>H06/026</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor Andrew Carr</name>
      <address>St Vincent's Hospital
HIV Clinical Trials Unit
Xavier 4
390 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>020 8382 3438</phone>
      <fax>02 8382 3489</fax>
      <email>acarr@stvincents.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Robyn Richardson</name>
      <address>St Vincent's Hospital
HIV Clinical Trials Unit
Xavier 4
390 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>02 83823872</phone>
      <fax>02 83822090</fax>
      <email>rrichardson1@stvincents.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Robyn Richardson</name>
      <address>St Vincent's Hospital
HIV Clinical Trials Unit
Xavier 4
390 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>02 83823872</phone>
      <fax>02 83822090</fax>
      <email>rrichardson1@stvincents.com.au</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Andrew Carr</name>
      <address>St Vincents Hospital
Xavier, Level 4
390 Victoria St
Darlinghurst
NSW 2010</address>
      <phone>+61 2 8382 3359</phone>
      <fax />
      <email>acarr@stvincents.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>